JamesMForanMD

Oncology • Jacksonville, FL

Hematologic Oncology

Associate Professor of Oncology, Mayo Clinic Cancer Center, Mayo Clinic Florida

Join to view full profile

Dr. Foran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Foran's full profile

Already have an account?

Office
4500 San Pablo Rd S
Jacksonville, FL 32224
Phone+1 904-953-2000

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1995
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1993
University of ManitobaClass of 1990

Certifications & Licensure

FL State Medical License 2011 - 2025
AL State Medical License 2003 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia Start of enrollment: 2004 Jan 01
Completed
Phase 1
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens Start of enrollment: 2006 Jul 01
Terminated
Phase 2
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
Completed
Phase 2
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas Start of enrollment: 2008 Jun 01
Terminated
Early Phase 1
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2025-02-01
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.
Talha Badar, Keith L Knutson, James Foran, Naseema Gangat, Kevin D Pavelko
Blood Advances. 2025-01-28
Randomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2025-01-10

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine

Abstracts/Posters

Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Ly...
James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (A...
James M. Foran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Friday Scientific Workshop on Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact
60th American Society of Hematology Annual Meeting - 11/30/2018
Integrative Epidemiology: Translating Epidemiology and Basic Science to Maximize Clinical Impact
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Actinium Pharmaceuticals, Inc. To Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTRApril 19th, 2022
Pulling Back the Curtain: Uma Borate, MDAugust 2nd, 2021
New Integrated Clinical Studies UnitDecember 16th, 2019
Join now to see all